NCT05833594

Whole-course Immunonutrition Combined With Chemoradiotherapy±ICIs for Local Advanced Patients With Inoperable Esophageal Squamous Cell Carcinoma

Anhui Provincial Hospita

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 70 (estimated)
• Sponsor: Anhui Provincial Hospital · Other Government
• Sex: All
• Age: 18 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

Chemoradiotherapy has been a standard modality for inoperable locally advance esophageal carcinoma. The goal of this randomized control study is to compare the feasibility, and survival benefits of whole-course immunonutrition combined with chemoradiotherapy±ICIs for local advanced patients with inoperable esophageal squamous cell carcinoma. The main questions it aims to answer are: • If the feasibility and safety of whole-course immunonutrition combined with chemoradiotherapy±ICIs is better. • If the survival benefits (1, 2 and 3-years progression free survival) of whole-course immunonutrition combined with chemoradiotherapy±ICIs is longer. The Experimental group will receive a combination immunonutrition of omega-3 fatty acids, and glutamine, whereas the control group will receive standard formula.

Conditions

• Esophageal Squamous Cell Carcinoma
• Chemoradiotherapy
• Immunonutrition
• Inoperable

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	Whole-course Immunonutrition Combined With Chemoradiotherapy±ICIs	The Experimental group received a combination of omega-3 fatty acids, and glutamine, whereas the control group received standard formula.

Timeline

• Start date: 2023-07-01
• Primary completion: 2026-01-01
• Completion: 2026-12-01
• First posted: 2023-04-27
• Last updated: 2023-12-26

Locations

1 site across 1 country: China